logo
logo
Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Limited

NASDAQ•RGC
CEO: Mr. Yat-Gai Au
セクター: Healthcare
業種: Drug Manufacturers - Specialty & Generic
上場日: 2021-07-16
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. The company focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. Regencell Bioscience Holdings Limited was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
連絡先情報
Chinachem Leighton Plaza, 9th Floor 29 Leighton Road, Causeway Bay, Hong Kong
852-2155-0823
www.regencellbioscience.com
時価総額
$13.19B
PER (TTM)
-3680.9
38.4
配当利回り
--
52週高値
$83.60
52週安値
$0.09
52週レンジ
32%
順位58Top 85.6%
2.3
F-Score
改良版 Piotroski 分析
7年ファンダメンタル
弱い • 2.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2019-2025

財務ダッシュボード

Q4 2025 データ

売上高

$0.00+0.00%
直近4四半期の推移

EPS

-$0.00+0.00%
直近4四半期の推移

フリーCF

$0.00+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Net Loss Significantly Reduced Net losses decreased 18% to $3.58M in FY2025 from $4.36M in FY2024, reflecting improved operational efficiency.
Operating Expenses Down 20% Total operating expenses fell 20% to $3.77M in FY2025 compared to $4.74M last year, driven by lower marketing spend.
Cash Burn Rate Decreased Net cash used in operating activities improved 22%, totaling $3.11M used in FY2025 versus $4.00M used in FY2024.
CEO Maintains Strong Control Founder Yat-Gai Au beneficially owns 88.6% of Ordinary Shares, ensuring significant influence over corporate decisions and strategy.

リスク要因

Continued Operating Losses Expected Company expects to incur increasing operating losses for the foreseeable future as product development costs continue without revenue generation.
Substantial Going Concern Doubt Management concluded substantial doubt exists regarding ability to continue as a going concern without securing necessary additional capital financing.
Regulatory Approval Dependency Business success is entirely dependent on timely completion of research studies and obtaining regulatory approval for the TCM formula.
Unproven TCM Formula Efficacy Efficacy results stem from uncontrolled studies; standardized formula has not yet demonstrated safety or efficacy comparable to established treatments.

見通し

Focus on Hong Kong Launch Primary goal is to commercialize the standardized liquid-based TCM formula initially within the Hong Kong market after regulatory success.
Seek Pharmaceutical Partnerships Aim to form partnerships with leading pharmaceutical companies to accelerate R&D efforts for upcoming clinical trials and data integrity.
Explore Broader TCM Applications Intend to conduct further research on the TCM base formula for potential wider application across other neurological disorders.
Integrate Digital Health Ecosystem Concept planning underway to integrate AI algorithms, Blockchain technology, and cryptocurrency to optimize stakeholder value creation.

同業比較

売上高 (TTM)

DaVita Inc.DVA
$13.64B
+6.5%
Grifols, S.A.GRFS
$8.30B
+7.3%
Avantor, Inc.AVTR
$6.58B
-3.6%

粗利益率 (最新四半期)

Verona Pharma plcVRNA
95.4%
+0.0pp
Merus N.V.MRUS
94.7%
+55.6pp
Axsome Therapeutics, Inc.AXSM
93.0%
+1.1pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
VRNA$72.68B-145.1-30.0%42.7%
RVMD$18.55B-18.9-49.2%7.0%
RGC$13.19B-3680.9-61.9%9.5%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

財務レポート
財務データ
全年度

  • Form 20-F - FY 2025

    会計期末: 2025年6月30日|提出日: 2025年10月31日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.01+17.2%
    不明

  • Form 20-F - FY 2024

    会計期末: 2024年6月30日|提出日: 2024年10月25日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.01+26.9%
    不明

  • Form 20-F - FY 2023

    会計期末: 2023年6月30日|提出日: 2023年10月27日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.01+20.7%
    不明

  • Form 20-F - FY 2022

    会計期末: 2022年6月30日|提出日: 2022年10月31日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.01-435.7%
    不明

  • Form 20-F - FY 2021

    会計期末: 2021年6月30日|提出日: 2021年10月29日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.00-64.7%
    不明